RE: Seed Clinical Trials Presented6 Jun 2024 08:31
Thanks for posting that BK and noting the clinically meaningful results ""A multi-species synbiotic (DS-01) alleviates irritable bowel syndrome symptoms while boosting synbiotic consortium: A randomized, double-blind, placebo-controlled clinical trial."
This clinical trial assessed the impact of DS-01® in patients with Irritable Bowel Syndrome (IBS). Key findings include:
DS-01® led to a significant and clinically meaningful improvement in abdominal pain among participants with IBS.
DS-01® led to an enrichment of synbiotic and endogenous beneficial bacteria.
DS-01® led to a significant increase in serotonin in IBS-M participants, a potential mechanism of action.
These presentations will detail the methodology and results from the two clinical trials which have important implications for the application of microbiome science in consumer health and well-being.
Seed's Health clinical data on DS-01® Daily Synbiotic for antibiotic recovery and IBS will be presented in the session "Prebiotics, Probiotics and Synbiotics in Health and Disease" on May 20, 2024, from 12:30 PM to 1:30 PM EDT."
I hat PBX at the very least did not see fit to at least issue a RNS Reach announcing this, after all Seed Health account for most of the re venue generated here so anything that can lead to a meaningful increase in DS01 sales will have a material impact on revenue surely?